You are here
Professor David Cunningham
Director of the Royal Marsden/Institute of Cancer Research NIHR Biomedical Research Centre and Director of Clinical Research
Summary of current role
Professor David Cunningham is a Consultant Medical Oncologist and Head of the Gastrointestinal and Lymphoma Unit at the Royal Marsden Hospital in London and Surrey. He is also the Director of the Royal Marsden/Institute of Cancer Research NIHR Biomedical Research Centre and Director of Clinical Research.
Research activities and publications
His main research interests are clinical trials in gastrointestinal cancer and lymphoma, along with the development of translational research and novel molecular therapies.
Professor Cunningham is on the Editorial Board of Annals of Oncology, British Journal of Cancer and Current Colorectal Cancer Reports. He is Deputy Editor of Clinical Colorectal Cancer and was previously on the Editorial Board for the New England Journal of Medicine.
He has authored over 500 peer-reviewed publications during the past 25 years, many of which have been practice-changing and informing.
National/International Committees and Advisory Boards
Professor Cunningham is a faculty member of the ICR. He is a member of numerous professional societies including the British Association for Cancer Research, the European Society for Medical Oncology (ESMO) and the American Society for Clinical Oncology (ASCO). He has also been on the academic faculty and scientific committees of ESMO and ASCO.
He was elected to the Academy of Medical Sciences in June 2011. He is Chair of the Joint Royal Colleges of Physicians Training Board Specialist Advisory Committee in Medical Oncology and is Chair of the London Cancer Alliance Medical Oncology Training Committee. He is also the Chair of the National Cancer Research Institute (NCRI) Oesophago-Gastric Clinical Studies sub-group. He is a Committee member and previous Chair of the NCRI Upper GI Clinical Studies Group and a previous member of the NCRI Lymphoma Clinical Studies Group and NCRN Operational Steering Group.
Articles commented by Professor Cunningham
Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy
Samson P, Puri V, Robinson C, Lockhart C, Carpenter D, Broderick S, Kreisel D, Krupnick AS, Patterson GA, Meyers B, Crabtree TAnn Thorac Surg. 2016 Apr 12. [Epub ahead of print]
Bekkar S, Gronnier C, Renaud F, Duhamel A, Pasquer A, Théreaux J, Gagnière J, Meunier B, Collet D, Mariette C; French Eso-Gastric Tumors (FREGAT) working group, Fédération de Recherche EN CHirurgie (FRENCH) and Association Française de Chirurgie (AFC)Br J Surg. 2016 Apr 4. [Epub ahead of print]
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al.Lancet Oncol. 2015 Sep;16(9):1090-8.